Ken-Ichi Fujita

11PUBLICATIONS
5CO-AUTHORS
Immunogenetics (incl. genetic immunology)AllergyPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 23, 2026
ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma.

|Nov 24, 2025
Association of IL12RB2, RORC, and class II HLA polymorphisms with severe erythema multiforme of regorafenib in Japanese patients with colorectal cancer.

Geonwoo Lee, Remi Murase, Natsumi Matsumoto

|Jul 01, 2025
ABCC4 polymorphism indirectly reduces systemic exposure to a capecitabine metabolite 5'-deoxy-5-fluorouridine in Japanese subjects.

Natsumi Matsumoto, Ayano Oishi, Shotaro Yoshino

|Mar 08, 2024
Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer.

Koutaro Ono, Remi Murase, Natsumi Matsumoto

|Dec 10, 2023
Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice.

Yang Li, Yasuhiro Kazuki, Thomas Drabison

|Aug 31, 2023
A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer.

Yukitaka Shibata, Natsumi Matsumoto, Remi Murase

Pageof 2

Frequent Collaborators

1 joint publications

Hiromi Okuyama

1 joint publications

Seigo Nakamura

1 joint publications

Yang Li

1 joint publications

Shuiying Hu